NextCure’s (NASDAQ:NXTC) quiet period will end on Tuesday, June 18th. NextCure had issued 5,000,000 shares in its IPO on May 9th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. During NextCure’s quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
NXTC has been the subject of a number of analyst reports. Piper Jaffray Companies started coverage on NextCure in a research report on Monday, June 3rd. They issued an “overweight” rating and a $26.00 price target for the company. Morgan Stanley started coverage on NextCure in a research report on Monday, June 3rd. They set an “overweight” rating and a $25.00 target price for the company.
Shares of NextCure stock opened at $14.49 on Thursday. NextCure has a 1 year low of $13.93 and a 1 year high of $22.75.
There is no company description available for NextCure Inc
Further Reading: CD Ladder
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.